BHRC BLOG
GLP-1 Peptides: How They Work (And Why Everyone’s Talking About Them)
Peptide Therapy
GLP-1 peptides have become the most discussed advance in metabolic medicine in decades. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have made headlines not just for weight loss, but for what they’re revealing about how hunger, metabolism, and weight regulation actually work at a biological level.
But how do GLP-1 peptides actually work? Why do they produce dramatically different results than previous weight loss medications? And who are they appropriate for? This guide answers all of it — based on the clinical evidence, not the hype.
What Is GLP-1?
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after you eat. It serves several critical functions:
- Signals the pancreas to release insulin in response to glucose (blood-sugar regulation)
- Suppresses glucagon (the hormone that tells the liver to release stored glucose)
- Slows gastric emptying — food leaves the stomach more slowly, extending the feeling of fullness
- Acts directly on appetite centers in the hypothalamus and brainstem to reduce hunger drive
In people with obesity, GLP-1 signaling is often impaired — the natural GLP-1 response after eating is blunted, which means the brain doesn’t receive adequate “I’m full” signals. This isn’t a willpower problem. It’s a hormonal problem. GLP-1 receptor agonists correct it pharmacologically.
Why Natural GLP-1 Isn’t Enough
- Natural GLP-1 has a half-life of only 2–3 minutes — it’s rapidly broken down by the enzyme DPP-4
- GLP-1 receptor agonists (like semaglutide) are engineered to resist DPP-4 breakdown, giving them a half-life of ~7 days at the injectable dose
- This sustained exposure is what produces appetite suppression potent enough to result in 15–22% weight loss in trials
The Science: How GLP-1 Peptides Produce Weight Loss
GLP-1 receptor agonists work through three distinct pathways simultaneously — which is why they’re so effective compared to earlier weight loss medications that targeted only one mechanism.
Pathway 01
Central Appetite Suppression
GLP-1 receptors in the hypothalamus and brainstem regulate the body’s “hunger set point.” When these receptors are continuously activated by a long-acting GLP-1 agonist, the brain’s appetite drive is fundamentally reduced — patients report simply not feeling hungry, rather than resisting hunger through willpower.
Pathway 02
Gastric Motility Reduction
GLP-1 slows gastric emptying — the rate at which food leaves the stomach and enters the small intestine. This extends the mechanical sensation of fullness after a meal and slows glucose absorption, blunting post-meal blood sugar spikes. This is partly why nausea is a common early side effect — the stomach is emptying more slowly than patients are accustomed to.
Pathway 03
Insulin Secretion and Glucose Homeostasis
GLP-1 stimulates insulin secretion in a glucose-dependent manner — it enhances insulin release only when blood glucose is elevated. This is key to its safety profile; unlike older diabetes medications, GLP-1 agonists don’t cause hypoglycemia in non-diabetic patients because they won’t stimulate insulin when glucose is already normal.
Semaglutide vs. Tirzepatide: What’s the Difference?
Semaglutide — GLP-1 Agonist
Semaglutide (Wegovy for weight loss, Ozempic for diabetes) is a modified version of natural GLP-1, engineered to be highly resistant to DPP-4 degradation. It binds to the GLP-1 receptor with high affinity and maintains that binding for approximately 7 days per weekly injection.
The STEP-1 trial (2021) showed an average of 14.9% body weight loss over 68 weeks in non-diabetic adults with obesity — roughly 2–3x the efficacy of any previously approved weight loss medication. The SELECT trial (2023) demonstrated a 20% reduction in major cardiovascular events in overweight patients with established heart disease, making semaglutide the first weight loss medication to demonstrate this level of cardiovascular benefit.
Tirzepatide — Dual GLP-1/GIP Agonist
Tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) is a “twincretin” — a single molecule that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.
GIP is another gut hormone released after eating, and its receptors are present in the hypothalamus, fat cells, and other tissues. By activating both receptors, tirzepatide produces a synergistic effect on appetite suppression and fat metabolism that exceeds either receptor’s activation alone.
What to Expect: A Timeline
Who Qualifies for GLP-1 Therapy?
At BHRC, GLP-1 therapy is appropriate for adults who meet one or more of the following criteria:
- BMI ≥30, or BMI ≥27 with a weight-related condition (type 2 diabetes, hypertension, high cholesterol, sleep apnea)
- Documented difficulty achieving or maintaining weight loss through lifestyle modification alone
- Metabolic syndrome or insulin resistance
- Cardiovascular disease with overweight or obesity
GLP-1 therapy is not appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, current pancreatitis, or certain other conditions. A full medical history review is conducted before any prescription is issued.
The Muscle Loss Question
One important clinical nuance: rapid weight loss from any source — dietary restriction, GLP-1 therapy, or surgery — results in some loss of lean muscle mass. Studies suggest approximately 25–39% of weight lost on GLP-1 monotherapy is lean mass rather than fat.
BHRC protocols address this directly:
- Resistance training recommendations — muscle-preserving exercise is integrated into every weight loss protocol
- Protein intake optimization — most patients significantly under-consume protein; our protocols include specific targets
- GH peptide add-on — for patients losing a significant amount of weight, we may add CJC-1295/Ipamorelin to stimulate growth hormone and support lean mass preservation
GLP-1 Therapy at BHRC
Our approach is physician-supervised from start to finish. Every patient starts with a consultation that includes a review of metabolic labs, cardiovascular risk factors, current medications, and weight history. We don’t take a one-size-fits-all approach — the right agent, the right dose, and the right adjunct protocols are individualized.
Consultations are available in person or virtually, so you can start your evaluation from anywhere.
Beverly Hills Rejuvenation Center
Ready to Learn If GLP-1
Therapy Is Right for You?
Book a free consultation with a BHRC physician — in person or virtually. We’ll review your health history, goals, and labs to determine the right protocol for you.
Book a Free ConsultationGLP-1 Therapy Locations
BHRC offers GLP-1 weight loss consultations at all six of our primary locations, with virtual consultations available nationally.
West Hollywood
California
West Los Angeles
California
Paradise Valley
Arizona
Westlake Village
California
Valencia
California
Nevada
Frequently Asked Questions
What is GLP-1 and what does it do?
GLP-1 is a gut hormone released after eating that signals the pancreas to release insulin, slows gastric emptying, and reduces appetite via the hypothalamus. GLP-1 receptor agonists like semaglutide mimic and amplify these effects to produce sustained weight loss.
How is GLP-1 different from other weight loss medications?
Earlier weight loss drugs stimulated the sympathetic nervous system or blocked fat absorption. GLP-1 agonists work at the hormonal and neurological level — resetting the hunger set point in the brain — which produces larger, more sustained results with a better cardiovascular safety profile.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 agonist (single target). Tirzepatide is a dual GLP-1/GIP agonist with stronger average results — 22.5% vs. 14.9% body weight loss in respective pivotal trials.
How long do I have to take GLP-1 medication?
GLP-1 therapy is generally considered long-term. STEP-4 data showed significant weight regain after stopping semaglutide. Your BHRC physician will discuss maintenance protocols and lifestyle strategies to support long-term outcomes.
What are the side effects of GLP-1 peptides?
The most common are GI-related (nausea, constipation, reduced appetite) — especially during dose titration. These typically improve within 4–8 weeks. BHRC’s gradual titration protocol is designed to minimize early side effects.
Can GLP-1 medications help with more than weight loss?
Yes. Clinical evidence supports benefits for type 2 diabetes, cardiovascular disease risk reduction (20% fewer major events in SELECT), NAFLD, kidney disease, and potentially sleep apnea and heart failure.
Will I lose muscle on GLP-1 medication?
Some lean mass loss occurs during any significant caloric deficit — approximately 25–39% of weight lost on GLP-1 therapy is lean mass. BHRC protocols include resistance training guidance and optional GH peptide add-ons to preserve muscle.
How do I get started with GLP-1 therapy at BHRC?
Book a consultation — in person or virtually. A BHRC physician will review your labs, health history, and goals to determine the right protocol for you.
1. Wilding JPH et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM, 2021. STEP-1 trial.
2. Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM, 2022. SURMOUNT-1 trial.
3. Lincoff AM et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” NEJM, 2023. SELECT trial.
4. Rubino DM et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance.” JAMA, 2021. STEP-4 trial.
